Y-mAbs Therapeutics (YMAB) Financial Report Summaries

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

External links

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: affidavit, alliance, clarify, comparison, ensuing, FSBC, guideline, IRC, killer, mediation, Nobelpharma, Princeton, propensity, radiolabled, retrospective, score, screening, slightly, Subtopic, upto

Removed: abroad, ACA, academic, adapt, added, adding, Additionally, administered, administering, advice, advisory, Affordable, aggregate, agree, announcement, anticancer, apply, appointment, approve, area, arise, arising, assist, assure, attain, attribute, attributed, ballot, bankruptcy, beneficiary, Biden, blinded, breach, budget, cabinet, collection, comparator, competing, conclude, conclusion, confidentiality, Congressional, considerable, contemplated, convicted, costly, counteract, cover, created, creating, criteria, decision, derivative, desirable, determination, devote, difficulty, disagree, discretion, donut, Dr, education, employed, employment, enacted, EU, excel, exclusivity, fashion, fee, felony, fewer, formulating, framework, frequency, gain, gathered, generic, governing, governmental, harm, heavily, heightened, hole, identified, impacted, impaired, impede, implementation, importation, impose, independent, induce, insolvency, insufficient, intense, intention, interpretation, IRA, join, joined, Juan, knowledge, landlord, leave, legislative, limit, lose, lowering, lucrative, manufacturer, marketed, Medicare, medicinal, member, metropolitan, motivate, negatively, notified, observed, ODAC, owed, Pedro, person, pivotal, point, premise, prescribed, prescription, President, pressure, prevent, principal, procedure, profitability, profitably, promotional, promulgated, quickly, recommending, recruit, reduced, regulate, relation, reliable, reliably, reliant, remain, reputation, request, restrict, retaining, reviewing, salary, San, scrutiny, security, selection, separate, serve, skilled, sponsor, stating, statistical, stringent, submission, survival, suspended, sustain, Switching, talent, territory, transitioned, transparency, turnover, typically, unavailable, uncured, unsatisfactory, verify, violated

From filing 10-Q 2024 Q3

Financial report summary

Competition

Perspective Therapeutics • Elbit Imaging • United Therapeutics • MacroGenics • QSAM Biosciences • Actinium Pharmaceuticals • Gamida Cell • BeiGene • Fusion Pharmaceuticals • POINT Biopharma Global

Management Discussion

The $1.5 million, or 7%, decrease in product revenue, net was due to decreased product revenue, net from international markets and also in the United States. Our international product revenue, net was $3.1 million for the three months ended September 30, 2024, a decrease of 19% compared to $3.9 million in the three months ended September 30, 2023. Product revenue, net from international markets includes $1.3 million from Latin America driven by recurring orders following commercial launches in Brazil and Mexico in the second quarter of 2024, and $1.0 million from Eastern Asia. Product revenue, net from Western Europe in the three months ended September 30, 2023 included $3.0 million of product revenue, net from our distribution partner, WEP. Our distribution partner in Western Europe operates our named patient program in the region. We did not have any shipments to Western Europe region in the three months ended September 30, 2024. Product revenue, net from the United States was $15.3 million and $16.1 million for the three months ended September 30, 2024 and 2023, respectively, representing a 5% decline primarily due to an unfavorable price mix, partially offset by increased volume.